Core Viewpoint - The company, WuXi AppTec, is experiencing positive market performance, with a recent stock increase of 1.78% and a total market capitalization of 287.87 billion yuan, benefiting from its position as a leading Contract Research Organization (CRO) and the depreciation of the Chinese yuan [1][3]. Group 1: Company Overview - WuXi AppTec is an international leader in providing comprehensive and integrated new drug research and production services for the global biopharmaceutical industry [2]. - The company is a domestic leader in the pharmaceutical outsourcing industry, being one of the earliest to engage in CRO and CMO integrated services, with over 200 authorized and pending patent achievements [2]. - The main business involves the discovery, research, and production of small molecule chemical drugs, offering a full range of services to global pharmaceutical companies [2][7]. Group 2: Financial Performance - For the period ending September 30, 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, reflecting an 84.84% increase [7]. - The company’s revenue from overseas accounts for 78.67%, benefiting from the depreciation of the yuan [3]. - The revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [7]. Group 3: Market Activity - The stock has seen a net inflow of 1.84 million yuan from major investors today, with a total net inflow of 2.38 million yuan over the last three days [4][5]. - The average trading cost of the stock is 95.67 yuan, with the current price approaching a resistance level of 96.50 yuan, indicating potential for upward movement if this level is surpassed [6].

Core Viewpoint - MediXis has shown a positive stock performance with a year-to-date increase of 10.87% and significant gains in recent trading periods, indicating strong market interest and potential growth in the biopharmaceutical sector [2]. Group 1: Stock Performance - As of January 6, MediXis's stock price increased by 2.01%, reaching 62.53 CNY per share, with a trading volume of 30.23 million CNY and a turnover rate of 0.36%, resulting in a total market capitalization of 8.40 billion CNY [1]. - The stock has risen by 8.58% over the last five trading days and 17.45% over the last twenty days, while experiencing a slight decline of 1.23% over the past sixty days [2]. Group 2: Company Overview - MediXis, established on February 2, 2004, and listed on November 5, 2019, is located in the Pudong New Area of Shanghai and specializes in providing comprehensive new drug research and development services to pharmaceutical companies and other drug research institutions [2]. - The company's revenue composition includes 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research, with a minor contribution of 0.01% from other services [2]. - MediXis is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, and is associated with concepts such as CRO, specialized and innovative enterprises, margin financing, MSCI China, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, MediXis reported a revenue of 843 million CNY, reflecting a year-on-year growth of 5.14%, while the net profit attributable to shareholders was -29.68 million CNY, showing a significant increase of 76.93% compared to the previous year [2]. - Since its A-share listing, MediXis has distributed a total of 158 million CNY in dividends, with cumulative payouts of 33.94 million CNY over the past three years [3]. Group 4: Shareholder Information - As of September 30, the number of shareholders for MediXis reached 16,500, an increase of 27.83% from the previous period, with an average of 8,149 circulating shares per person, which decreased by 21.96% [2].

Core Viewpoint - Kailaiying's stock price has shown a slight increase of 2.01% year-to-date, with fluctuations in trading volume and market capitalization, indicating a mixed performance in the short term [1] Group 1: Stock Performance - As of January 5, Kailaiying's stock price reached 94.80 yuan per share, with a trading volume of 1.10 billion yuan and a turnover rate of 0.37%, resulting in a total market capitalization of 34.184 billion yuan [1] - Year-to-date, Kailaiying's stock has increased by 2.01%, but it has decreased by 1.27% over the last five trading days, increased by 4.36% over the last 20 days, and decreased by 16.46% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.630 billion yuan, representing a year-on-year growth of 11.82%, and a net profit attributable to shareholders of 800 million yuan, reflecting a year-on-year increase of 12.66% [2] - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [2] Group 3: Shareholder Structure - As of September 30, 2025, Kailaiying had 60,100 shareholders, an increase of 45.37% compared to the previous period, with an average of 0 circulating shares per shareholder [2] - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, while a decrease was observed in holdings by Huabao Zhongzheng Medical ETF [2]

Group 1 - The core viewpoint of the articles highlights the recent stock performance and financial results of Nanmo Biological, indicating a slight increase in stock price and significant growth in revenue and net profit [1][2] - As of January 5, Nanmo Biological's stock price rose by 2.07% to 41.86 CNY per share, with a total market capitalization of 3.264 billion CNY [1] - The company has experienced a year-to-date stock price increase of 2.07%, with a 14.29% year-on-year revenue growth of 303 million CNY for the period from January to September 2025 [1] Group 2 - Nanmo Biological's main business involves the research, production, and sales of genetically modified animal models, with revenue contributions from standardized models (48.34%), model technical services (21.92%), breeding (19.50%), and customized models (9.34%) [1] - The company has distributed a total of 30.0413 million CNY in dividends since its A-share listing, with 10.0047 million CNY in the last three years [2] - As of September 30, 2025, the number of shareholders increased by 2.53% to 6,687, while the average circulating shares per person decreased by 2.47% to 11,658 shares [1]

《生物安全法案》复盘 --如何看待地缘政治对中国CXO企业的影响？ 行业研究 · 行业专题 医药生物 · 医疗研发外包 投资评级：优于大市（维持评级） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 请务必阅读正文之后的免责声明及其项下所有内容 1 报告摘要 证券研究报告 | 2025年12月28日 n 靴子落地，美国《2026财年国防授权法案》夹带《生物安全法案》生效。 请务必阅读正文之后的免责声明及其项下所有内容 2 ü 《2026财年国防授权法案》夹带《生物安全法案》（主要指第851节《禁止与特定生物技术公司签订合同》）落地，标志着美国已将生物安全正式纳入国家防务与 安全战略框架统筹考量，同时彰显其在生物技术供应链自主可控的明确政策转向，本质是中美的科技竞争与产业安全博弈在生物领域的延 ...

【导读】百花医药或易主，自12月29日开市起停牌 中国基金报记者 闻言 12月26日晚间，百花医药发布公告称，公司控股股东、实际控制人米在齐、米恩华、杨小玲正在筹划公司股份协议转让事宜，可能导致公司控制权发生变 更。 百花医药计划自12月29日开市起停牌，预计停牌时间不超过2个交易日。12月26日收盘，百花医药股价报12.24元/股，涨幅达5.88%，总市值为47.07亿元。 筹划股份转让前解除一致行动关系 公告显示，2025年12月1日，米在齐、米恩华、杨小玲及其一致行动人李建城确认不再续签《一致行动人协议书》，一致行动关系自动解除。 2024年12月2日，米在齐、米恩华、杨小玲及其一致行动人李建城签署《一致行动人协议书》，有效期一年，合计持有百花医药24.58%的股份。 如今，米在齐、米恩华、杨小玲仍为百花医药控股股东、实际控制人，李建城不再是百花医药控股股东、实际控制人之一致行动人，其所持百花医药股份 不再合并计算。 具体来看，米在齐、米恩华、杨小玲直接持有百花医药股份的比例分别为8.99%、6.70%、4.99%。 | 姓名/名称 | 持股数量(股) | 持股比例 | | --- | --- | -- ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Medisi, indicating a stock price increase of 92.38% year-to-date and a market capitalization of 7.798 billion yuan [2] - Medisi's stock price reached 58.04 yuan per share with a trading volume of 81.93 million yuan and a turnover rate of 1.06% as of December 23 [1] - The company has seen a net inflow of main funds amounting to 1.4455 million yuan, with significant buying and selling activities recorded [1] Group 2 - Medisi's business primarily involves providing comprehensive new drug research services to pharmaceutical companies and other new drug research institutions, with revenue composition being 50.34% from preclinical research and 49.64% from drug discovery and pharmaceutical research [2] - As of September 30, the number of shareholders increased by 27.83% to 16,500, while the average circulating shares per person decreased by 21.96% to 8,149 shares [2] - For the period from January to September 2025, Medisi achieved an operating income of 843 million yuan, reflecting a year-on-year growth of 5.14%, while the net profit attributable to the parent company was -29.6849 million yuan, showing a significant year-on-year increase of 76.93% [2] Group 3 - Medisi has distributed a total of 158 million yuan in dividends since its A-share listing, with cumulative distributions of 33.9365 million yuan over the past three years [3]

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

Group 1 - The core viewpoint of the news is that BaiO Technology's stock has experienced a decline of 22.28% this year and an 8.61% drop in the last five trading days, with current trading activity showing a slight increase in stock price [1] - BaiO Technology is a Chinese company primarily engaged in antibody drug research and preclinical research services, established on November 13, 2009, and listed on December 10, 2025 [2] - The company operates five divisions, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [2] Group 2 - BaiO Technology is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing [2] - The company is associated with several concept sectors, including cell therapy, innovative drugs, pre-profit and profit growth, newly listed stocks, and specialized and innovative enterprises [2]

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]